US Patent

US10772883 — Diketopiperazine microparticles with defined specific surface areas

Formulation · Assigned to Mannkind Corp · Expires 2030-06-11 · 4y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects diketopiperazine microparticles with a specific surface area of less than about 67 m2/g, which can be used to deliver a drug.

USPTO Abstract

Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

Drugs covered by this patent

Patent Metadata

Patent number
US10772883
Jurisdiction
US
Classification
Formulation
Expires
2030-06-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.